GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

139.3B

Vuru Grade

75.00/100

Current Price

$91.27
+1.4318 (+1.59%)

Growth Price

$29.96
Overvalued by 67.18%

Stability Price

$16.82
Overvalued by 81.57%

Company Metrics

  • 20.35 P/E
  • 7.86 P/S
  • 8.33 P/B
  • 4.414 EPS
  • 39.33% Cash ROIC
  • 0.34 Cash Ratio
  • 0 / 0% Dividend
  • 11.84M Avg. Vol.
  • 1.53B Shares
  • 139.3B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call
Motley Fool - Jul 22, 2014
I'd like to see Gilead buy an oncology company with a drug or two already on the market. Gilead has idelalisib under review for a couple of a couple different blood cancers and a pipeline of other oncology drugs, but no experience selling cancer drugs.
Gilead trounces earnings views, but shares don't feel the after-hours love - MarketWatch (blog)
Gilead hepatitis C drug Sovaldi racks up $3.5 billion in quarter - Reuters
Why I'm Bullish On Gilead Sciences, Inc. (GILD)
ETF Daily News - 11 hours ago
bullish buy Tyler Laundon: Biotech bears were tearing apart the sector in Q1 of this year. And it got ugly. They all questioned the potential for a repeat performance for biotech in 2014.
Expect Gilead Sciences To Outperform (GILD) - Seeking Alpha (registration)
Why Gilead Sciences (GILD) Stock Is Up Today - TheStreet.com
Gilead Sciences, Inc. (GILD): The Bullish Case For The Stock
ETF Daily News (blog) - 7 hours ago
Gilead also reported net income of $3.66 billion, which trounced the $772.6 million from the same period last year. For Gilead, the biggest driving force continues to be its signature drug Sovaldi, which is used to treat hepatitis C. According to the ...
How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C ...
TheStreet.com - Jul 21, 2014
NEW YORK (TheStreet) -- Shares of Gilead Sciences Inc. (GILD) are up 0.80% to $89.90 in pre-market trade as the company's Solvadi, controversial because of its price, helps cure hepatitis C in people with HIV, according to researchers who say the drug ...
Gilead Sciences, Inc. (NASDAQ:GILD), reported earnings and revenue that ...
Street Register - 13 hours ago
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific.
FDA Okays Gilead Sciences Inc's Zydelig for Blood Cancers
Nature World News - Jul 24, 2014
The U.S. Food and Drug Administration said Wednesday that it has okayed Gilead Sciences Inc's Zydelig for treatment of three types of blood cancers.
Gilead Sciences Price Target Increased to $127.00 by Analysts at Maxim Group ...
WKRB News - 13 hours ago
Gilead Sciences, Inc. logo Research analysts at Maxim Group increased their price target on shares of Gilead Sciences (NASDAQ:GILD) from $112.00 to $127.00 in a report released on Monday.
US senators ask Gilead Sciences to explain high cost of hepatitis C drug
Los Angeles Times - Jul 11, 2014
Two U.S. senators asked Gilead Sciences Inc. to produce documents explaining why its new hepatitis C drug is priced at $84,000 per treatment course, raising renewed concerns over the high costs to taxpayers.
Gilead Sciences: The Senate Just Wrote Me a Letter - Barron's (blog)
Trade-Ideas: Gilead (GILD) Is Today's New Lifetime High Stock - TheStreet.com
Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE ...
Tech News - 14 hours ago
AbbVie is developing an experimental triple-pill regimen for hepatitis C as a competitor to Gilead Sciences Inc.'s drug Sovaldi, which reaped $3.5bn in the second quarter.
Update: Gilead Sciences Earnings (GILD)
Seeking Alpha (registration) - Jul 24, 2014
In my previous article about Gilead titled, "Gilead Sciences: Cause For Concern?", I noted that "a forward P/E of 14 is ludicrous".